Recurrent miscarriage affects women of childbearing age worldwide. Vascular endothelial dysfunction and immunological impairment are associated with recurrent miscarriage To date, there is no effective or optimal therapeutic approach for these condition. Hydroxychloroquine has endothelial protective action via ant diabetic, lipid lowering, antioxidant effects or direct endothelial protection. Hydroxychloroquine is an antimalarial and immunomodulatory agent. In pregnancy, hydroxychloroquine is prescribed for inflammatory conditions associated with adverse perinatal outcomes such as systemic lupus erythematosus, antiphospholipid syndrome and placental inflammatory lesions such as chronic histiocytic intervillositis, hydroxychloroquine has therapeutic potential to improve placental function in pregnancies associated with heightened inflammation.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
156
400mg
5 mg
75 mg
Abdel-rahman Mahmoud Mohammed
Asyut, Egypt
Number of viable fetuses at 20 weeks gestation
Time frame: 5 months
Number of patients with miscarriage before 20 weeks
Time frame: 5 months
Number of pregnancy complications such as ( FGR or preeclampsia, IUFD after 20 week gestation)
Time frame: 9 months
Number of fetus with Major congenital anmalies
Time frame: 9 months
Number of Live birth
Time frame: 9 months
Number of Preterm delivery before 37 week gestation.
Time frame: 8 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.